Drug Target Review

SEPTEMBER 25, 2024

However, this will not be straightforward, given that non-oncogene resistance is driven by complex transcriptional networks, and the key drivers that determine how these mechanisms could be targets for drug development remain elusive.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

JANUARY 31, 2021

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. Trimer-Tag© is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.

Clinical Trials 52

Clinical Trials Vaccine Trials Virus 52

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

At the same time, it is understandably important to be able to measure and characterize a treatment’s effect over time. However, with this most recent approval, FDA did not leave the question of durability as something to be answered postapproval, which signals to us that this issue looms large in FDA’s preapproval regulation of gene therapies.

Therapies 119

Therapies FDA FDA Approval Treatment 119

Nvidia Developer: Drug Discovery

APRIL 20, 2020

To help make the process for scientists more accessible, we’re spotlighting a few of the GPU-accelerated applications that developers can use right now in the fight against this virus. Molecular dynamics simulations offer accurate approximations of real molecular behavior, which is useful in different stages of drug development.

Small Molecule 52

Small Molecule Virus Laboratories Science 52

The Pharma Data

JANUARY 4, 2021

USA) to develop and commercialize gene therapy products based on adeno-associated virus (AAV) vectors to treat inherited eye diseases. The company’s pipeline is built on two proprietary adeno-associated virus (AAV) technology platforms. . MUNICH, Germany, Jan. Nasdaq: BIIB, Cambridge, Mass.,

Therapies 52

Therapies Virus Disease Licensing 52

The Pharma Data

DECEMBER 3, 2020

Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope. Trimer-Tag © is an innovative drug development platform which allows the production of novel, covalently-trimerized fusion proteins.

Vaccine 52

Vaccine Immune Response Virus RNA 52

Alta Sciences

JULY 25, 2024

TOP MANUFACTURING AND ANALYTICAL SCIENTIFIC RESOURCES Podcast: Successful Manufacturing of Clinical Trial Supply Join our formulation and pharmacy experts as they share insider secrets for overcoming clinical trial challenges and resolving issues that could impact your drug development program's timeline. the UK, or the EU.

Science 52

Science Clinical Trials Clinical Pharmacology FDA 52

The Pharma Data

JANUARY 31, 2021

We are proud to be collaborating with Clover on the development of this vaccine for COVID-19 and committed to supporting Clover in making the vaccine available globally.” Similar to other enveloped RNA viruses such as HIV, RSV and Influenza, SARS-CoV-2 is also an RNA virus that has a trimeric spike (S) protein on its viral envelope.

Vaccine 52

Vaccine Trials Virus RNA 52

The Pharma Data

DECEMBER 31, 2020

Reimer replaces Charlotte Russel and will be responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. She most recently served as senior Medical Director at Ferring Pharmaceuticals in Copenhagen. Source link.

Engineering 52

Engineering Pharmaceuticals Clinical Development Virus 52

The Pharma Data

DECEMBER 28, 2020

Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Annamycin for treatment of soft tissue sarcomas. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

DECEMBER 30, 2020

31, 2020 /PRNewswire/ — ImmVira Group Company (“the Company”), a biotechnology platform dedicated to the development of oncolytic virus(“OV”) and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing.

Virus 40

Virus International Trials Clinical Trials 40

Alta Sciences

JANUARY 11, 2024

There are three primary vectors employed in gene therapy: adeno-associated virus (AAV), adenovirus, or lentivirus vectors. In each issue, they share their decades of knowledge to help sponsors along their early-phase drug development journeys, as well as explore the latest challenges and innovations in the industry.

Therapies 52

Therapies Immune Response Disease Virus 52

The Pharma Data

OCTOBER 30, 2020

About REGN-COV2 REGN-COV2 is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

DECEMBER 14, 2020

” Under the license agreement, the development of ABBV-47D11 will be greatly advanced. Under the collaboration agreement, researchers are looking into the elimination of the SARS-CoV-2 virus and virally infected cells by K-NK cells.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

NOVEMBER 1, 2020

Pureos invests exclusively in private innovative drug development companies, with a special emphasis on the next generation of biological drugs and drug modalities. About Pureos Bioventures Pureos Bioventures is a newly formed venture capital fund, advised by Bellevue Asset Management.

Therapies 52

Therapies Science Treatment Disease 52

The Pharma Data

OCTOBER 16, 2020

Novan has been evaluating the ability of its NITRICIL platform technology as a potential nasal treatment option for Covid-19, announcing its potential efficacy as an antiviral against SARS-CoV-2, the virus that causes Covid-19.

Clinical Trials 52

Clinical Trials Trials Pharma Companies Clinical Research 52

The Pharma Data

DECEMBER 22, 2020

Currently, EME is focusing on the drug discovery/medical fields and working on using our proprietary technology to discover biological and medium sized molecular drug development candidates, as well as use VHH in cell/gene therapy. View source version on businesswire.com: [link]. Source link.

Engineering 52

Engineering Pharmaceuticals Drugs Protein Production 52

The Pharma Data

JANUARY 31, 2021

Gilead and Gritstone will develop an HIV-specific therapeutic vaccine using Gritstone’s proprietary prime-boost vaccine platform, comprised of self-amplifying mRNA (SAM) and adenoviral vectors, with antigens developed by Gilead. This press release features multimedia. View the full release here: [link].

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

DECEMBER 17, 2020

About casirivimab and imdevimab Casirivimab and imdevimab (formerly known as REGN-COV2 or REGEN-COV2) is a cocktail of two monoclonal antibodies (also known as REGN10933 and REGN10987, respectively) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.

Hospitals 52

Hospitals Production Clinical Trials Virus 52

Agency IQ

FEBRUARY 12, 2024

The pilot focused on identifying commonalities across products using Adeno-Associated Virus (AAV) vectors to reduce duplication of efforts across individual therapeutic programs and to encourage the field to move away from the current “one-disease-at-a-time approach.”

FDA 40

FDA Therapies Clinical Trials Disease 40

The Pharma Data

OCTOBER 19, 2020

Caris Pharmatech Just-In-Time Clinical Trial Solutions focus on rapid site activation and patient enrollment to streamline the drug development process. With over 200 research sites within the Caris Pharmatech Just-In-Time (JIT) Oncology Network, biopharma companies can identify and enroll more patients, faster.

Clinical Trials 52

Clinical Trials RNA DNA Science 52

The Pharma Data

NOVEMBER 16, 2020

This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. The Company plans to submit data from the full Phase 3 COVE study to a peer-reviewed publication. They are an inspiration to us all.

Vaccine 52

Vaccine Clinical Trials FDA Disease 52

The Pharma Data

SEPTEMBER 17, 2020

“Based on our initial clinical studies, we believe that virus neutralizing antibodies, including LY-CoV-555, could play an important role in the fight against COVID-19,” said Daniel Skovronsky , M.D., Lilly ‘s chief scientific officer and president of Lilly Research Laboratories.

Therapies 52

Therapies Production Government Disease 52

Agency IQ

JUNE 29, 2023

Title Type Date Received by OIRA Legal Deadline Clinical Considerations for Studies of Devices Intended to Treat Opioid Use Disorder Draft Guidance June 12 None Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under PEPFAR Unknown June 12 None Prescription (..)

FDA 40

FDA Science Regulations Production 40

The Pharma Data

DECEMBER 5, 2020

Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, infectious diseases, pain and rare diseases.

Production 40

Production Trials Treatment Disease 40

Covalent Modifiers

JANUARY 14, 2024

Chloroacetamide inhibitor 13 and epoxide inhibitor 30 were found to inhibit cellular SARS-CoV-2 replication with an EC68 (half-log reduction of virus titer) of 3 and 5 μM. These compounds represent new pharmacological leads for anti-SARS-CoV-2 drug development.

Virus 189

Virus Drug Development Disease Drugs 189

The Premier Consulting Blog

JUNE 18, 2023

This has opened new opportunities in pharmaceutical drug development, such as the ability to evaluate large complex databases and to integrate information in useful ways. One exciting application of these technologies is the use of in silico trials in the development of novel therapies for rare diseases.

Drug Development 52

Drug Development Disease Clinical Trials Drugs 52

Codon

FEBRUARY 13, 2024

doi: 10.2210/rcsb_pdb/goodsell-gallery-048 The Virus that Cures It’s been over 25 years since the science magazine Discover first ran an extraordinary article about how a long-forgotten medical treatment, used in the former Soviet country of Georgia, could save us from the growing threat of untreatable, drug-resistant infections.

Therapies 138

Therapies Virus DNA Clinical Trials 138

Drug Target Review

JANUARY 15, 2024

Each T cell expresses a TCR specific for an HLA‑presented peptide signal, and when that signal is detected a T cell expressing the relevant TCR can launch a complex array of immune effector responses that can suppress or destroy tumours or virus-infected cells.

Engineering 110

Engineering DNA Virus Immune Response 110

PerkinElmer

APRIL 21, 2020

Although the novel coronavirus is the subject of nearly every media story right now, several years ago it was the Zika virus (ZIKV) gathering a great deal of attention. Here, we describe the novel use of high content imaging solutions (HCS) in a study to identify possible Zika virus inhibitors that could be translated into therapeutic form.

Virus 52

Virus FDA Approval Laboratories Vaccine 52

The Pharma Data

JANUARY 12, 2021

. “Patients in our antibody cocktail outpatient clinical trial experienced significant reductions in virus levels and required fewer medical visits for COVID-19, suggesting the therapy can help reduce the current burden on hospitals and healthcare systems,” said George D. Yancopoulos , M.D.,

Government 52

Government Hospitals Virus Clinical Trials 52

EG Life Sciences

FEBRUARY 15, 2023

The year 2022 reflected a transformative path for the drug development industry. Every year, the FDA’s Center for Drug Evaluation and Research (CDER) clarifies to drug developers required study design elements, as well as other data needed on the drug application to support a full and comprehensive assessment.

Drug Development 52

Drug Development FDA Approval Drugs Virus 52

Drug Target Review

JULY 7, 2023

For autoantibody diseases, new discoveries in immunology are leading to profound learnings about drivers of disease, helping us to expand the development of medicines more rapidly and effectively. Antibodies are proteins that guard against foreign substances that enter our bodies,such as bacteria, fungi, viruses and toxins.

Disease 98

Disease Immune Response Therapies Treatment 98

Drug Target Review

MAY 16, 2024

This suggests that the field of drug discovery is primed for a paradigm shift in the fundamental strategy of how diseases are treated. Drug development, driven by courageous ambition and the resolution of diseased states, instead should be focused on re-establishing homeostasis.

Disease 64

Disease Therapies Medical Schools Treatment 64

The Pharma Data

OCTOBER 21, 2020

The COVID-19 pandemic has highlighted the urgent need for a novel, oral antiviral to treat this highly infectious and often deadly virus,” said Jean-Pierre Sommadossi, Ph.D., “Roche shares our passion for delivering innovative new medicines to address great unmet medical needs. Chief Executive Officer and Founder of Atea Pharmaceuticals.

RNA 52

RNA Pharmaceuticals Virus Clinical Trials 52

The Pharma Data

FEBRUARY 25, 2022

. “There remains an urgent need for SARS-CoV-2 therapeutic agents that target parts of the virus other than the spike protein that are not as likely to evolve.” According to Jose, these enzymes are relatively stable; therefore, they are unlikely to develop drug-resistant mutations rapidly.

FDA Approval 52

FDA Approval Molecular Biology FDA Virus 52

The Pharma Data

FEBRUARY 18, 2022

Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose. Nirsevimab is being developed by AstraZeneca in collaboration with Sanofi. Data from the MELODY and MEDLEY trials will be published in an upcoming peer-reviewed journal.

Virus 40

Virus Trials Disease Clinical Trials 40